Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Holocene Advisors LP

by · The Cerbat Gem

Holocene Advisors LP cut its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 55.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 93,365 shares of the medical equipment provider’s stock after selling 115,704 shares during the period. Holocene Advisors LP’s holdings in Zimmer Biomet were worth $10,079,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Erste Asset Management GmbH acquired a new position in shares of Zimmer Biomet during the third quarter worth approximately $4,476,000. Auxier Asset Management boosted its position in shares of Zimmer Biomet by 3.4% during the third quarter. Auxier Asset Management now owns 63,573 shares of the medical equipment provider’s stock worth $6,863,000 after buying an additional 2,070 shares during the period. Public Sector Pension Investment Board boosted its position in shares of Zimmer Biomet by 7.5% during the third quarter. Public Sector Pension Investment Board now owns 8,620 shares of the medical equipment provider’s stock worth $931,000 after buying an additional 600 shares during the period. Providence Capital Advisors LLC lifted its position in Zimmer Biomet by 8.6% in the third quarter. Providence Capital Advisors LLC now owns 52,800 shares of the medical equipment provider’s stock worth $5,700,000 after purchasing an additional 4,191 shares during the period. Finally, FORA Capital LLC lifted its position in Zimmer Biomet by 6.6% in the third quarter. FORA Capital LLC now owns 38,314 shares of the medical equipment provider’s stock worth $4,136,000 after purchasing an additional 2,371 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of research analyst reports. JPMorgan Chase & Co. cut their target price on Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating for the company in a research report on Monday, September 16th. Oppenheimer dropped their price target on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a report on Tuesday, October 15th. BTIG Research dropped their price target on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a report on Thursday, October 3rd. Evercore ISI dropped their price target on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Finally, Wolfe Research began coverage on Zimmer Biomet in a report on Tuesday, September 10th. They issued a “peer perform” rating on the stock. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $123.22.

View Our Latest Stock Analysis on Zimmer Biomet

Zimmer Biomet Stock Up 0.2 %

ZBH stock opened at $110.74 on Wednesday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. Zimmer Biomet Holdings, Inc. has a 52-week low of $101.47 and a 52-week high of $133.90. The company has a 50-day moving average of $107.41 and a two-hundred day moving average of $109.15. The stock has a market capitalization of $22.05 billion, a price-to-earnings ratio of 21.05, a price-to-earnings-growth ratio of 2.03 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting analysts’ consensus estimates of $1.74. The business had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The firm’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.65 earnings per share. As a group, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Company Profile

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Read More

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report).